bierre_price
$PTPDF From a NuWays research:
„Pentixapharm sits at the intersection of a high-prevalence indication and one of the fastest-growing fields of medicine: radiopharma. Following the recent capital increase, the company is now well positioned to enter Phase 3 with its lead diagnostic agent PentixaFor from a position of financial strength, with several catalysts ahead.
Financing secured. PTP has placed the full c. 11.0m new shares at € 1.85, raising net proceeds of c. € 19.7m. Anchor shareholder Eckert Wagniskapital (c. 36%) exercised the rights issue in full and the residual tranche was materially oversubscribed. Pro forma cash of c. € 25m (eNuW), vs. c. € 5m previously, extends the runway from Q1 2027 into early 2028 and covers the initial execution phase of PANDA, the Phase 3 study for PentixaFor (eNuW).
As a result, the company can comfortably enter this next stage, with two key catalysts ahead: